The Basic Principles Of Piceatannol 4'-O-?-D-glucopyranoside
All enrolled sufferers who gained at the least a person dose of zosuquidar or placebo for the duration of induction were being monitored for your event of adverse gatherings (439 patients, 219 on zosuquidar and 210 on placebo). The most typical adverse events had been relevant to the duration of extended and sizeable myelosuppression as is expected